The Board of Medicine has unveiled a membership program that welcomes both healthcare professionals and members of the public. With an emphasis on psychedelic therapy and wearable health technology, the group aims to advance innovative approaches to patient care.

AbbVie is set to acquire Gilgamesh Pharmaceuticals’ bretisilocin, a next-generation psychedelic compound with promising Phase 2 results for major depressive disorder. The treatment’s short-acting properties and robust clinical data highlight its potential to address critical gaps in current psychiatric therapies.